Clinical Research Directory
Browse clinical research sites, groups, and studies.
Thymosin-α1 for Recurrent Implantation Failure
Sponsor: Fakih IVF Fertility Center
Summary
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Official title: Thymosin-α1 for Recurrent Implantation Failure Following Transfer of PGT-a Tested Embryo: A Randomized, Double-Blind, Placebo-Controlled Trial
Key Details
Gender
FEMALE
Age Range
18 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
136
Start Date
2026-02-11
Completion Date
2027-06
Last Updated
2026-10-15
Healthy Volunteers
No
Conditions
Interventions
Thymosin Alpha1
Start at luteal start in ART cycles and continue until 10+6 weeks' gestation.
Placebo Control
Matching placebo injections on the same schedule and duration.
Locations (1)
Fakih IVF
Abu Dhabi, United Arab Emirates